Related Experiment Video
Updated: Jun 5, 2026

A Novel in vivo Gene Transfer Technique and in vitro Cell Based Assays for the Study of Bone Loss in Musculoskeletal Disorders
Published on: June 8, 2014
Therapeutic targeting of osteoclast function and pathways
Matthew L Broadhead1, Jonathan C M Clark, Crispin R Dass
1St. Vincent's Hospital, Department of Orthopaedics and University of Melbourne, Department of Surgery, L3, Daly Wing, 35 Victoria Parade, Fitzroy 3065, VIC, Australia.
Introduction:
Osteoclasts are responsible for bone resorption and underlie a number of pathological states in which osteolysis is a feature. Over recent decades our molecular understanding of osteoclast differentiation and activation has expanded significantly, and this has allowed for the development of a number of osteoclast-targeted therapies.
Areas Covered:
This review seeks to present the underlying molecular mechanisms of osteoclast differentiation and activity as a basis for understanding our current treatment of osteoporosis and malignant tumors in bone. Osteoclast-targeted therapies are also being evaluated for the treatment of rheumatoid arthritis, osteosarcoma and giant cell tumor of bone.
Expert Opinion:
With concurrent advances in the fields of molecular biology, pathology and advanced imaging, osteoclast-targeted therapies show great potential for treating conditions in which excess resorption of bone is a key pathological process. Targeting of osteoclast control mechanisms offers the potential of combining 'molecular imaging' with therapeutic intervention and longitudinal monitoring of disease processes.
Insights
Osteoclast targeted therapies offer promising treatments for bone diseases like osteoporosis and cancer. Advances in molecular biology and imaging enhance their potential for combined therapy and monitoring.
Area of Science:
- Bone biology and pathology
- Molecular mechanisms of bone resorption
- Therapeutic strategies for bone diseases
Background:
- Osteoclasts are critical for bone resorption, and their dysregulation contributes to pathological bone loss.
- Significant advancements in understanding osteoclast differentiation and activation have paved the way for targeted therapies.
- Osteolysis is a hallmark of various diseases, necessitating effective osteoclast-modulating treatments.
Purpose of the Study:
- To review the molecular mechanisms governing osteoclast differentiation and activity.
- To provide a foundation for understanding current treatments for osteoporosis and bone tumors.
- To explore the potential of osteoclast-targeted therapies in various bone pathologies.
Main Methods:
- Literature review focusing on molecular mechanisms of osteoclast biology.
- Analysis of current therapeutic approaches for bone resorption disorders.
- Evaluation of emerging osteoclast-targeted therapies.
Main Results:
- Detailed exposition of molecular pathways controlling osteoclastogenesis and function.
- Identification of key targets for therapeutic intervention in bone diseases.
- Overview of ongoing research and clinical trials for osteoclast-targeted treatments.
Conclusions:
- Osteoclast-targeted therapies hold significant promise for treating conditions characterized by excessive bone resorption.
- Integration of molecular imaging with therapeutic interventions allows for precise monitoring of disease progression.
- Future directions include refining therapeutic strategies and leveraging advanced imaging for personalized medicine in bone disorders.
Related Concept Videos
Osteoclasts in Bone Remodeling
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Bone Remodeling
Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
